Modifying Metabolic Syndrome and Cardiovascular Risk for Prostate Cancer Patients on ADT Using a Risk Factor Modification Program and Continuous Fitbit Monitoring

This study tests whether a structured risk-reduction program (diet, exercise, and cardiovascular monitoring using a Fitbit) can help reduce heart disease risk and metabolic problems in men with prostate cancer who are taking hormone-blocking therapy (ADT — androgen deprivation therapy). ADT is an effective cancer treatment but often causes weight gain, diabetes risk, and heart issues. **You may be eligible if...** - You are a man with confirmed prostate cancer that has spread or has come back after local treatment - You have been on hormone-blocking therapy (GnRH agonist, antagonist, or surgical castration) for at least 3 months - Your cancer is stable or improving on treatment - You are expected to remain on hormone therapy for at least 6 more months - You are willing to wear a Fitbit and participate in the program **You may NOT be eligible if...** - You have uncontrolled diabetes, severe heart disease, or other major conditions that make exercise unsafe - You are unable to participate in a physical activity program Talk to your doctor to see if this trial is right for you.